US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Inspire Corporate Bond ETF

24.19

-0.0200-0.08%

Volume:51.51K

Turnover:1.25M

Market Cap:478.96M

PE:- -

High:24.28

Open:24.17

Low:24.17

Close:24.21

52wk High:24.85

52wk Low:22.84

Shares:19.80M

Float Shares:19.80M

Volume Ratio:0.93

T/O Rate:0.26%

Dividend:1.02

Dividend Rate:4.20%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

ACROBiosystems and Partners Conclude OrganoAsia 2025

Press Release: Spyre Therapeutics Announces Grants of Inducement Awards

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

C4X Discovery announces selection of a once-daily development candidate from its α4β7 inhibitor programme

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

Roche Holding Ltd (RHHBY.US) Invests $400 Million in IBD Sector with Preclinical Oral Small Molecule Development

Press Release: Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil(R)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IBD/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":24.19,"timestamp":1772053200000,"preClose":24.21,"halted":0,"volume":51512,"delay":0,"changeRate":-0.0008261049153242286,"floatShares":19800000,"shares":19800000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.02,"latestTime":"02-26 04:19:12 EST","open":24.17,"high":24.277,"low":24.17,"amount":1245874.4268,"amplitude":0.00442,"askPrice":29.57,"askSize":100,"bidPrice":19.44,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772116200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":24.19,"sharesOutstanding":19800000,"nav":24.18,"aum":478802924.01,"dividendRate":0.042001,"bidAskSpread":0.00124,"postHourTrading":{"tag":"盘后","latestPrice":24.19,"preClose":24.19,"latestTime":"16:10 EST","volume":10,"amount":241.9,"timestamp":1772053804182,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.926370327897299},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":19800000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.926370327897299,"shares":19800000,"dividePrice":1.016,"high":24.277,"amplitude":0.00442,"preClose":24.21,"low":24.17,"week52Low":22.84,"pbRate":"--","week52High":24.85,"institutionHeld":0,"latestPrice":24.19,"eps":0,"divideRate":0.042001,"volume":51512,"delay":0,"ttmEps":0,"open":24.17,"prevYearClose":24.2,"prevWeekClose":24.22,"prevMonthClose":24.15,"prevQuarterClose":24.2,"fiveDayClose":24.26,"twentyDayClose":24.21,"sixtyDayClose":24.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2026-02-24","symbol":"IBD","amount":0.0779,"announcedDate":"2026-02-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-24","defaultRemindTime":1771943400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-02","payableDate":"2026-02-24","currency":"USD","dateTimestamp":1771909200000,"payDate":"2026-03-02"},{"date":"2026-01-27","symbol":"IBD","amount":0.0592,"announcedDate":"2026-01-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-27","defaultRemindTime":1769524200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-27","currency":"USD","dateTimestamp":1769490000000,"payDate":"2026-02-02"},{"date":"2025-12-17","symbol":"IBD","amount":0.121,"announcedDate":"2025-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-17","defaultRemindTime":1765981800000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-17","currency":"USD","dateTimestamp":1765947600000,"payDate":"2025-12-24"},{"date":"2025-11-21","symbol":"IBD","amount":0.0729,"announcedDate":"2025-11-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-21","defaultRemindTime":1763735400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-26","payableDate":"2025-11-21","currency":"USD","dateTimestamp":1763701200000,"payDate":"2025-11-26"},{"date":"2025-10-28","symbol":"IBD","amount":0.0824,"announcedDate":"2025-10-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-28","defaultRemindTime":1761658200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-03","payableDate":"2025-10-28","currency":"USD","dateTimestamp":1761624000000,"payDate":"2025-11-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575375784","title":"Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2575375784","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575375784?lang=en_us&edition=fundamental","pubTime":"2025-10-15 20:00","pubTimestamp":1760529600,"startTime":"0","endTime":"0","summary":"Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance  VANCOUVER, Wash","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/15/3167012/0/en/Absci-to-Host-KOL-Seminar-on-ABS-201-Androgenetic-Alopecia-Program-on-December-11-2025-Announces-Accelerated-Initiation-of-Phase-1-2a-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","HST","KOL","BK4585","BK4588","IBD","BK4181"],"gpt_icon":0},{"id":"2575528054","title":"Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2575528054","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575528054?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:01","pubTimestamp":1760385660,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Oct.  13, 2025  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165784/0/en/Spyre-Therapeutics-Announces-Proposed-Public-Offering-of-its-Common-Stock-and-Pre-Funded-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","USA","BK4539","BK4007","IBD"],"gpt_icon":0},{"id":"2574143601","title":"ACROBiosystems and Partners Conclude OrganoAsia 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2574143601","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574143601?lang=en_us&edition=fundamental","pubTime":"2025-10-10 09:21","pubTimestamp":1760059260,"startTime":"0","endTime":"0","summary":"- Leading Scientists from China, Japan and South Korea Convene to Drive Organoid Research and Commercialization   TOKYO, Oct. 10, 2025 /PRNewswire/ -- ACROBiosystems, together with Leica Biosystems, Molecular Devices, and Leica Microsystems, hosted the OrganoAsia 2025-The Frontier of Organoid Science in Beijing. The hybrid-format conference featured an in-person opening session alongside a live online stream, drawing more than 500 experts and researchers—primarily from China, Japan, and South Korea, with additional global attendees—to examine recent progress and future directions for organoid technology in precision medicine, drug discovery, and regenerative medicine.","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2780465/image_5024610_12421859.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2780465/image_5024610_12421859.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/acrobiosystems-and-partners-conclude-organoasia-2025-302580426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEA.AU","IBD","BK7004"],"gpt_icon":0},{"id":"2572633851","title":"Press Release: Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2572633851","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572633851?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:05","pubTimestamp":1759521900,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Oct. 03, 2025  -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 42,500 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on October 1, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease  and other immune-mediated disease products by combining best-in-cla","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4539","NQmain","BK4139","IBD","SYRE"],"gpt_icon":0},{"id":"2572351484","title":"Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel","url":"https://stock-news.laohu8.com/highlight/detail?id=2572351484","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572351484?lang=en_us&edition=fundamental","pubTime":"2025-10-02 19:51","pubTimestamp":1759405860,"startTime":"0","endTime":"0","summary":"AUSTIN, TX and DURHAM, NC, Oct.  02, 2025  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/02/3160287/0/en/Shattuck-Labs-Announces-Participation-in-Upcoming-Wedbush-Securities-Key-Opinion-Leader-KOL-and-Company-Panel.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","BK4139","KOL","STTK"],"gpt_icon":0},{"id":"2569320967","title":"C4X Discovery announces selection of a once-daily development candidate from its α4β7 inhibitor programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2569320967","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569320967?lang=en_us&edition=fundamental","pubTime":"2025-09-22 15:00","pubTimestamp":1758524400,"startTime":"0","endTime":"0","summary":"C4X Discovery Holdings Ltd  C4X Discovery announces selection of a once-daily development candidate from its α4β7 inhibitor programme A potent and selective α4β7 inhibitor with oral bioavailability to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/22/3153649/0/en/C4X-Discovery-announces-selection-of-a-once-daily-development-candidate-from-its-%CE%B14%CE%B27-inhibitor-programme.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD"],"gpt_icon":0},{"id":"2567049169","title":"Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2567049169","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567049169?lang=en_us&edition=fundamental","pubTime":"2025-09-15 09:18","pubTimestamp":1757899080,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  14, 2025  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commerc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/15/3149642/0/en/Successful-Commercial-Launch-of-Ryoncil-Highlighted-at-Global-Healthcare-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","BK4575","BK4006","MESO","IBD","HCSG","BK4139","MSB","MSC","BK4137"],"gpt_icon":0},{"id":"1190131189","title":"Roche Holding Ltd (RHHBY.US) Invests $400 Million in IBD Sector with Preclinical Oral Small Molecule Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1190131189","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190131189?lang=en_us&edition=fundamental","pubTime":"2025-09-02 21:18","pubTimestamp":1756819100,"startTime":"0","endTime":"0","summary":"On September 2nd, OMass Therapeutics announced it has entered into an exclusive collaboration and licensing agreement with Genentech, a member of the Roche Holding Ltd (RHHBY.US) group, granting the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RHHBY","03165","IBD"],"gpt_icon":0},{"id":"2563093309","title":"Press Release: Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil(R)","url":"https://stock-news.laohu8.com/highlight/detail?id=2563093309","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563093309?lang=en_us&edition=fundamental","pubTime":"2025-08-29 08:24","pubTimestamp":1756427040,"startTime":"0","endTime":"0","summary":"Mesoblast Chief Executive Dr. Silviu Itescu said, \"This has been a banner year for the Company, with achievement of FDA approval for Ryoncil , the first and only FDA approved mesenchymal stromal cell  product in the United States and a successful commercial launch of the product for treatment of steroid-refractory acute graft-versus-host disease  in pediatric patients aged 2 months and older .\". \"We are working tirelessly to transform Mesoblast into a fast-paced commercial biotechnology company with demonstrable sales of our first commercial product Ryoncil . We intend to deliver additional approved indications for sales of Ryoncil and to launch a next-generation platform technology into potential blockbuster indications including heart failure and chronic low back pain.\". -- Revenue from cell therapy products was US$17.2 million, up 191% on prior. -- Revenue growth was driven by successful launch of Ryoncil in the final. quarter, with US$13.2 million gross sales and US$11.3 million in","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0553294199.USD","BK7067","BK4139","03160","BK4585","BK7501","BANR","LU0545039389.USD","LU1559883803.SGD","BK4150","LU0738911758.USD","MESO","CMS","BK4099","IBD","CD","LU2637428348.USD","BK4555","BK4208","BK4141","BK4604","BK4022","BK4543","TM","BK4211","LU1894683264.USD","BK4116","ASX","MSC","BK4526","MSB.AU","BK4575","LU1894683348.USD","LU0566484027.USD","LU2500361329.USD","LU0949170772.SGD","BK7508","LU1003077747.HKD","BK4232","LU2346227817.USD","R","LU0661504455.SGD","NQmain"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":29,"code":"91000000","status":"200"}]}}